Allison DeAngelis
Reporter at STAT
Reporter covering biopharma startups and venture capital at @statnews. Formerly @thisisinsider and @bosbizjournal.
Articles
-
2 days ago |
statnews.com | Adam Feuerstein |Elaine Chen |Allison DeAngelis
On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech. The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a fun podcast when we can discuss a biotech acquisition.
-
1 week ago |
statnews.com | Allison DeAngelis |Adam Feuerstein |Elaine Chen
What does the MAHA Commission have planned for the drug industry? Why is Robert F. Kennedy Jr. targeting mRNA vaccines? And what are Adam and Elaine getting up to in Chicago? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. The American Society of Clinical Oncology, or ASCO, kicks off its annual meeting this weekend in Chicago. We discuss what to watch at the meeting.
-
1 week ago |
statnews.com | Allison DeAngelis
The world looked a little different when bioengineer Dan Huh first began exploring whether it was possible to replace mouse testing with small-scale replicas of human tissues. The iPhone was just hitting store shelves. The researchers who had discovered gene silencing through RNA interference had recently received a Nobel Prize. And a blonde, curly haired young woman by the name of Taylor Swift had just released her first album.
-
2 weeks ago |
statnews.com | Allison DeAngelis |Elaine Chen |Adam Feuerstein
What was the mood like at a big gene therapy conference last week? Why is Novo Nordisk’s CEO stepping down? And why has Adam been in such a good mood? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs.
-
3 weeks ago |
statnews.com | Allison DeAngelis
Biotech investment firm RA Capital has laid off staff at its internal startup incubator, STAT has learned, highlighting the instability among VCs as the biotech industry struggles to right itself. The cuts hit RA Ventures, or Raven, an incubator that creates and supports biotech startups. The Raven team has launched several biotechs over the years, including Aliada Therapeutics and Mariana Oncology, both of which were acquired last year.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 5K
- Tweets
- 4K
- DMs Open
- Yes
RT @statnews: What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public pers…
RT @statnews: The European Commission unveiled a $565 million package to retain and attract scientists, as other countries try to leverage…
Biopharma executives have remained largely quiet while the Trump admin has upended scientific organizations. But @JonathanWosen reports from a Stanford event that there are signs that life science veterans are beginning to rethink silence as a strategy. https://t.co/7Ee1erHaq1
